Gilead Collaboration with Sangamo
Kite, a Gilead Company and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for Cancer Kite, a Gilead (GILD) …
Gilead Sciences (GILD)
In the Limelight
This content is for members
Celgene Acquires Juno Therapeutics at $9 Billion – $87 a Share. Why Array is Trading Around $15 in Premarket Today.
Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which, Celgene has agreed to acquire Juno. Celgene will pay $87 per …
The Year in Review Part 1
This content is for members
Gilead’s New Acquisition: An important Step Forward Towards Building a Superior Cancer Franchise
This content is for members
A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.
The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed Outstanding news announced that leukemia patients who relapsed …
The Week in Review
This content is for members
The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect
Important news has come from the FDA, which issued new guidelines to speed the introduction of treatments with human cells and tissues, including gene therapy. …
The Week in Review
This content is for members
The Week in Review
This content is for members
Gilead’s CAR T Drug Yescarta Is Approved for NHL Resisting Previous Treatments
As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration (FDA) has given the green light to a second CART …
New Breakthrough Immuno-Oncology Products
This content is for members
Gilead’s Acquisition Effect on Other CAR-T Developers’ Stocks
This content is for members
The FDA Granted Novartis a Historical First CAR-T Approval for Leukemia. Can You Guess Who Will Be Granted the Second Historical CAR-T Approval?
The answer is, indeed, Gilead (GILD) and its CAR T drug approval will be for non-Hodgkin lymphoma (NHL). This is true, as in May, the FDA has accepted for …
Why Our Increased Enthusiasm for Incyte’s Product Baricitinib
This content is for members